Kairos Pharma (KAPA) Revenue (2025)
Kairos Pharma's (KAPA) quarterly Revenue came in at $100.0 million in Q1 2025.
Powered by 
Analysis
Kairos Pharma (KAPA) Revenue (2025) Analysis & Trends
Kairos Pharma (KAPA) has reported Revenue for 1 consecutive years, with $100.0 million the latest figure, recorded in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.02 Bn | 176.84 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 131.54 Bn | 123.69 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.96 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.23 Bn | 55.04 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.85 Bn | 48.72 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.88 Bn | 30.59 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Kairos Pharma | 31.79 Mn | 26.45 Mn | - | - |